Monitor this situation.

Unsubscribe anytime.

[SITUATION] · [ACTIVE] · [BUSINESS]

2 clusters · 6 sources · 17 days · First seen 18 days ago · Last updated 1 day ago

Celltrion Omlyclo European market expansion

Overview

Celltrion has expanded the availability of Omlyclo, its omaliizumab biosimilar for allergic asthma and chronic spontaneous urticaria, across major European markets. Following the initial release of 75mg and 150mg doses, the company launched a 300mg single-dose option in Germany, the United Kingdom, and France to improve patient convenience through single-injection administration.

The product is available in pre-filled syringes and auto-injectors, featuring enhanced stability that allows for a two-year refrigerated shelf life and a ‘re-refrigeration’ capability after room-temperature exposure.

As of July 2026, the biosimilar has seen significant commercial success in Southern Europe, achieving a market share exceeding 90% in Spain and surpassing initial sales targets in Italy. Celltrion is currently working to expand its presence across 26 European countries by participating in national tenders and strengthening direct sales networks with medical institutions.

Entities

Omlyclo · Celltrion · European Respiratory Society · Spain · Roland Buhl

Claims

What the coverage asserts, and how many sources carry each claim.

[● 3 SOURCES] Omlyclo is currently being sold in 26 European countries. www.biotimes.co.kr · kormedi.com · biz.heraldcorp.com
[● 3 SOURCES] Omlyclo's market share in Spain exceeded 90% as of July. www.biotimes.co.kr · kormedi.com · biz.heraldcorp.com
[● 3 SOURCES] Sales in Italy have exceeded initial business targets. www.biotimes.co.kr · kormedi.com · biz.heraldcorp.com
[● 3 SOURCES] Omlyclo is available in 75mg, 150mg, and 300mg dosages. www.biotimes.co.kr · kormedi.com · biz.heraldcorp.com
[● 3 SOURCES] Celltrion participated in the European Respiratory Society Congress in Barcelona. www.biotimes.co.kr · kormedi.com · biz.heraldcorp.com
[● 2 SOURCES] The product is offered via pre-filled syringes and auto-injectors. www.biotimes.co.kr · biz.heraldcorp.com
[● 2 SOURCES] Omlyclo is a biosimilar of Xolair used for allergic asthma and chronic spontaneous urticaria. kormedi.com · biz.heraldcorp.com
[● 2 SOURCES] Celltrion plans to participate in the Global Urticaria Forum 2026 in Berlin. www.biotimes.co.kr · biz.heraldcorp.com

Timeline

1 day ago

[BUSINESS] 4 sources
Celltrion's Omlyclo expands in Europe with 90% market share in Spain
Celltrion's omaliizumab biosimilar, Omlyclo, has achieved over 90% market share in Spain and exceeded sales targets in Italy as it expands across 26 European countries.
18 days ago

[BUSINESS] 4 sources
Celltrion launches 300mg Omlyclo biosimilar in Europe
Celltrion has launched its 300mg Omlyclo biosimilar in major European markets, offering improved dosing convenience and enhanced storage stability compared to the original medication.

Sources

biotimes.co.kr · biz.heraldcorp.com · kormedi.com · newstomato.com · techholic.co.kr · thebionews.net